OPKO Health Inc. (NASDAQ: OPK) subsidiary OPKO Biologics presented preclinical data for its drug candidate OPK8801001 at ENDO 2026, the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE